Salvianic Acid A Regulates Ferroptosis by Activating the Nrf2-GPX4 Pathway Through EGFR to Protect Myocardial Ischemia-Reperfusion Injury Authors: Lin Tu, Yuming Lu, Xingde Liu, Xiangchun Shen Published: 2026 ABSTRACT ObjectiveSalvianic acid A, known for its potent cardioprotective effects, is a promising therapeutic agent for myocardial ischemia-reperfusion (I/R) injury, a condition where ferroptosis plays a critical role. This study aims to explore the effect of Salvianic acid A on I/R injury through EGFR-Nrf2-GPX4-mediated ferroptosis.MethodsThe levels of ROS, GSH, GSSG, Fe2+, the state of ferroptosis, the expression and localization of Nrf2, and the expression of EGFR were all detected in hypoxia/reoxygenation (H/R) cells. The Nrf2 inhibitor ML385 and siRNA-EGFR were used to confirm the involvement of EGFR/Nrf2 in protecting cardiomyocytes from H/R-induced ferroptosis. Additionally, the regulatory effect of Salvianic acid A on EGFR/Nrf2/GPX4 were analyzed in the I/R animal model with EGFR inhibitors/agonists.ResultsSalvianic acid A inhibited ROS, Fe2+, GSH, GSSG, GSH/GSSG, and promoted GPX4 and SLC7A11 expressions in H/R cells. Further experiments demonstrated that Salvianic acid A promoted Nrf2 nuclear translocation and expression to inhibit ferroptosis, which was abolished by the Nrf2 inhibitor ML385. In addition, the molecular docking indicated that Salvianic acid A has a good binding activity with EGFR, and cell experiments also confirmed that Salvianic acid A promoted EGFR expression, which was required for its subsequent activation of Nrf2 and inhibition of ferroptosis, as verified by siRNA-EGFR. In vivo experiments showed that Salvianic acid A alleviated myocardial injury, inhibited ferroptosis, and this improvement was related to the regulation of NRF2-GPX4 by EGFR.ConclusionSalvianic acid A mediated ferroptosis through the EGFR-regulated NRF2-GPX4 pathway, ultimately improving myocardial I/R injury. Introduction Myocardial ischemia-reperfusion (I/R) injury poses a significant clinical challenge, as it leads to further structural and functional deterioration after reperfusion therapy for acute myocardial infarction, ultimately contributing to heart dysfunction and death.1 The pathophysiology of I/R is multifaceted, involving processes such as calcium overload, oxidative stress, inflammatory response, and various forms of cell death.2 A deeper investigation into its exact molecular mechanisms is therefore essential for developing effective interventions. Ferroptosis, a novel iron-dependent form of cell death, has been identified as a key contributor to myocardial I/R injury.3 In contrast to apoptosis and necrosis, ferroptosis is characterized by iron overload, lethal lipid peroxidation, and the inactivation of glutathione peroxidase 4 (GPX4).4 The transcription factor Nrf2, serves as the primary regulator of cellular antioxidant defenses, can transcriptionally activate the expression of antioxidant gene GPX4, significantly inhibiting ferroptosis.5,6 The Nrf2-GPX4 axis is recognized as a vital endogenous protective pathway against ferroptosis and the progression of I/R injury.7 The epidermal growth factor receptor (EGFR), a classic tyrosine kinase receptor, not only participates in cell proliferation and differentiation but has also been implicated in oxidative stress responses and cell survival.8 Recent studies have shown that the activation of EGFR can boost cellular antioxidant capacity by promoting the nuclear translocation and transcriptional activity of Nrf2,9,10 thereby upregulating the expression of GPX4 and suppressing ferroptosis.11 However, it remains unclear whether EGFR can inhibit ferroptosis by changeable the Nrf2-GPX4 axis to mitigate I/R injury in cardiomyocytes. Salvianic acid A (Danshensu), a phenolic aromatic acid isolated from the traditional Chinese herb Salvia miltiorrhiza, exhibits potent antioxidant and cardioprotective activities.12 It has been broadly applied in the cardiovascular diseases either alone or in combination,13 and can treat myocardial infarction by attenuating myocardial fibrosis, suppressing myocardial cell apoptosis, improving cellular metabolism, diminishing inflammatory responses, alleviating oxidative stress, enhancing hemorheology, and promoting angiogenesis.14,15 Moreover, evidence suggests that Salvianic acid A demonstrates anti-ferroptotic activity.16 It can alleviate brain damage by inhibiting oxidative damage and ferroptosis, in part through regulation of the Nrf2/GPX4 axis.17 The preliminary molecular docking results have confirmed that Salvianic acid A has a good binding activity with EGFR (Supplementary Figure 1). Although numerous researches have confirmed that Salvianic acid A mitigates I/R injury,18 it remains unclear whether its protective mechanisms involve regulation of ferroptosis, specifically, whether it precisely modulates the core Nrf2‑GPX4 pathway via EGFR signaling. The present research aims to systematically elucidate the efficacy of Salvianic acid A on ferroptosis following myocardial I/R injury, and to explore the interplay between EGFR and the Nrf2/GPX4-mediated ferroptotic cascade. Specifically, we will determine whether Salvianic acid A promoted Nrf2 transcriptional activity by activating EGFR, thereby inhibiting myocardial cell ferroptosis, ultimately achieving the protective effect on myocardial I/R injury. Material and Methods Cell Culture and Treatment The rat cardiomyocytes H9C2 (no. iCell-r012) were purchased from iCell (China) and cultured in a medium consisting of 89% DMEM (no. PM150210, Procell, China) + 10% FBS (no. C04001-500, Vivacell, China) + 1% Penicillin - Streptomycin mixture (no. S110JV, BasalMedia, China) at 37°C with 5% CO2, and the experiments design was structured to encompass four distinct components. The first part divided into the control group, H/R model group (H/R), H/R + Salvianic acid A low-dose group (200 μM, Salvianic acid A-low, no. HY-N1913, MCE, USA), H/R + Salvianic acid A high-dose group (300 μM, Salvianic acid A-high), H/R + ferroptosis inhibitor Fer-1 (20 μM, Fer-1, no. HY-100579, MCE, USA). The second part included the control, H/R, H/R + Salvianic acid A-low (200 μM), and H/R + Salvianic acid A-high (300 μM) groups. Based on the dose‑response results from the first two parts, the high dose (300 μM) of Salvianic acid A was selected for all subsequent mechanism experiments. The third part included control, H/R, H/R + Salvianic acid A-high (300 μM), and H/R + Salvianic acid A-high + Nrf2 inhibitor ML385 (5 μM, no. HY-100523, MCE, USA) groups. The fourth part included control, H/R, H/R + Salvianic acid A-high (300 μM), H/R + Salvianic acid A-high + siRNA-NC, and H/R + Salvianic acid A-high + siRNA-EGFR groups. After the cell confluence reached 70%, the medium was switched to high‑glucose DMEM supplemented with 1% FBS for synchronization treatment for 24 h before constructing the hypoxia/reoxygenation (H/R) model, and different treatments were carried out according to the groups. Each experiment was repeated independently at least three times (n=3 independent biological replicates). To establish the H/R model, cells underwent 12 h of hypoxia in serum- and glucose-free DMEM using a three-gas incubator (37°C, 5% CO2, 1% O2, and 94% N2). Following this, reoxygenation was initiated by replacing the medium with DMEM containing 1% FBS and transferring the cells to a normoxic incubator (37°C, 5% CO2, and 95% O2) for 24 h. The drugs in each group were administered for pre-treatment during the 24-hour synchronization period prior to H/R induction. Cell Transfection The siRNA-NC and siRNA-EGFR were purchased from GenePharma (China) and transfected the cells to intervene in the expression of EGFR. Approximately 2×105 cells/mL of H9C2 cells were collected and inoculated in 6-well plates at 37°C, 5% CO2 in a constant temperature incubator. After preparing the siRNA and transfection reagents into a transfection complex, it was added to the complete medium without the double antibody for culturing the adherent H9C2 cells. After 6 h of constant temperature culture, the complete medium was changed to continue culture for 42 h. CCK8 Analysis After H9C2 cells were subjected to different treatments, CCK8 reagent (no. BS350B, Biosharp, China) diluted in serum-free medium was added, and the cells were further cultured at 37°C and 5% CO2 for 2 h. The absorbance values of each well were measured using an enzyme reader (no. ELx800, BioTek, USA) at a wavelength of 450 nm, and the cell survival rate was calculated. Flow Cytometry The lipid reactive oxygen species (lipid-ROS) in cell and myocardial tissue samples were detected by flow cytometry. The tissue samples were washed with pre-cooled PBS, then ground with a grinder, and the cell suspension was collected and filtered through a 200-mesh cell sieve. It was centrifuged at 300 g for 5 min, washed with PBS, and then lysed in 3 times the volume of red blood cell lysis solution (no. G2015, Servicebio, China). The cell precipitate was collected. In addition, H9C2 cells from different treatment groups were collected. A pre-prepared 5 μM C11-BODIPY 581/591 staining solution (no. HY-D1301, MCE, USA) was applied to the cells at 37°C for 30 min. After staining, flow cytometry (no. Cytoflex, Beckman, China) was used for analysis. Immunofluorescence Staining The Nrf2 and p-EGFR proteins in rat H9C2 cells were observed through immunofluorescence staining. After washing the cell slides with PBS, the membrane-breaking solution (no. G1204, Servicebio, China) was incubated for 10 min, then washed with PBS. The bovine serum blocking solution (no. GC305010, Servicebio, China) treated for 20 min, the antibodies Nrf2 (1:400, no. 16396-1-AP, proteintech, China), p-EGFR (Y1045) (1:200, no. ab316155, abcam, UK), and p-EGFR (Y1068) (1:200, no. AF5797, Beyotime, China) were incubated at 4°C overnight, followed by incubation with the FITC-labeled goat anti-rabbit antibody (no. GB22303, Servicebio, China) at 37°C for 30 min. The DAPI staining solution (no. G1012, Servicebio, China) was incubated in the dark for 10 min to stain the cell nuclei, and then the mounting agent for anti-fluorescence attenuation was used for mounting. Following microscopy imaging, the mean fluorescence intensity was calculated. Real-Time Quantitative Polymerase Chain Reaction Total RNA was extracted from rat H9C2 cell samples using the total RNA extraction kit (no. BL1665A, Biosharp, China). The PrimeScript RT reagent kit (no. RR047A, Takara, China) removed genomic DNA and transcribed it into cDNA. Then, quantitative PCR was performed using the TB Green Premix Ex Taq II (Tli RNaseH Plus) (no. RR820A, Takara, China) on a QuantStudio real-time PCR system (ThermoFisher, USA). Gene-specific primers are listed in Table 1. Relative mRNA levels were quantified using the 2−ΔΔCT method.Table 1Primer Sequences Used in This TestGeneForward Primer (5′-3′)Reverse Primer (5′-3′)β-actinGGGAAATCGTGCGTGACATTGCGGCAGTGGCCATCTCHmox1AGCGAAACAAGCAGAACCCAGTCGCTGTGTGGCTGGTGTGTAAGGNqo1AGGCTGCTGTGGAGGCTCTGGCTCCCCTGTGATGTCGTTTCTGNrf2GCCTTCCTCTGCTGCCATTAGTCTGCCTTCAGTGTGCTTCTGGTTGAbbreviations: Hmox1, heme oxygenase 1; Nqo1, NAD (P)H quinone dehydrogenase 1; Nrf2, nuclear factor erythroid 2-related factor 2. Table 1Primer Sequences Used in This TestGeneForward Primer (5′-3′)Reverse Primer (5′-3′)β-actinGGGAAATCGTGCGTGACATTGCGGCAGTGGCCATCTCHmox1AGCGAAACAAGCAGAACCCAGTCGCTGTGTGGCTGGTGTGTAAGGNqo1AGGCTGCTGTGGAGGCTCTGGCTCCCCTGTGATGTCGTTTCTGNrf2GCCTTCCTCTGCTGCCATTAGTCTGCCTTCAGTGTGCTTCTGGTTGAbbreviations: Hmox1, heme oxygenase 1; Nqo1, NAD (P)H quinone dehydrogenase 1; Nrf2, nuclear factor erythroid 2-related factor 2. Primer Sequences Used in This Test Abbreviations: Hmox1, heme oxygenase 1; Nqo1, NAD (P)H quinone dehydrogenase 1; Nrf2, nuclear factor erythroid 2-related factor 2. Animals Experimental Design A total of 90 male SPF-grade C57BL/6J mice (6–8 weeks) were obtained from Sipeifu (Beijing) Biotechnology Co., Ltd (China). The animal license number is SCXK (Jing) 2024–0001. The experimental animals were raised in a barrier system with a temperature range of 20°C to 26°C and a relative humidity range of 30% to 70%. There was a 12-h day/night light cycle. After the animals adapted to the environment, they were randomly divided into the sham operation group (SHAM), I/R model group, I/R + Salvianic acid A treatment group (Salvianic acid A), I/R + Salvianic acid A + EGFR inhibitor AG1478 group (Salvianic acid A + AG1478), and the I/R + Salvianic acid A + EGFR agonist EGF group (Salvianic acid A + EGF). Randomisation was performed using a random number table generated by SPSS 22.0. To minimise potential confounders, cage locations were rotated weekly, and the order of treatment administration and sample collection was randomised across groups. The investigator performing the surgeries, administering treatments, and conducting outcome assessments was blinded to group allocation. Each group of mice was intervened with the corresponding drug before the operation, with Salvianic acid A (50 mg/kg) given via intraperitoneal injection for 14 consecutive days,15 and AG1478 (30 mg/kg, no. HY-13524, MCE, USA)19 and EGF (1 mg/kg, no. HY-P7067, MCE, USA)20 administered by intraperitoneal injection for 7 days. After the drug intervention, except for the Sham group, all the other groups of mice underwent the I/R model construction. The mice were anesthetized with 1% 50 mg/kg pentobarbital sodium, the pain response of the mice was checked, and once it disappeared, the surgery could begin. The small animal ventilator (no. DHX-100, Chengdu Instrument Factory, China) and external light source (no. 76312, RWDLS, China) were turned on, and the heart was exposed to perform coronary artery left anterior descending branch threading to tighten. When the mouse’s heart apex turned white, the thread was loosened after 30 min of ischemia, and blood flow was reperfused for 2 h. The sham group only threaded without tying. No a priori sample size calculation was performed. The sample sizes (sham: n=10; I/R, Salvianic acid A, Salvianic acid A+AG1478, Salvianic acid A+EGF: n=20 each) were determined based on previous published studies and our pilot experiments, which estimated a ~30–40% mortality rate in the I/R model. In the end, the sham group included 10 mice, with 10 surviving. The I/R, Salvianic acid A, Salvianic acid A + AG1478, and Salvianic acid A + EGF groups each included 20 mice, with 11, 14, 11, and 16 surviving, respectively. Animals that died during or immediately after surgery due to surgical failure (eg, excessive bleeding, failed coronary artery ligation) were excluded from the analysis. No other exclusion criteria were applied. After 24 h of I/R, cardiac ultrasound was performed on the mice to measure left ventricular ejection fraction (LVEF) and left ventricular shortening rate (LVFS). Echocardiography at 24 h post‑reperfusion is a widely accepted standard time point for assessing acute cardiac dysfunction following I/R injury,21,22 which allows direct correlation with molecular analyses performed at the same time point. After the experiment, the mice were deeply anesthetized via intraperitoneal injection of pentobarbital sodium (50 mg/kg), and subsequently euthanized by cervical dislocation after the animal lost consciousness, and the heart samples were collected. TTC Staining Four slices of mouse heart tissue, each with a thickness of 1 mm, were taken and placed in the preheated TTC solution (no. BMB2085, Bomeibio, China) at 37°C for 30 min. The heart slices were then washed with PBS, fixed with 10% neutral formaldehyde for 6 h, and photographed. Pathological HE Staining The fixed tissues of the heart were dehydrated by an automatic dehydration machine (no. JT-12S, WHJJ, China), embedded in paraffin, sectioned, then deparaffinized to water, stained with hematoxylin (no. H9627, Sigma-Aldrich, USA) for 5–10 min, differentiated with hydrochloric alcohol solution for 3 s, re-blotched with weakly alkaline solution, and stained with alcohol-soluble eosin (no. YE2080, BomeiBio, China) for 3 min. The sections were dehydrated with graded alcohol, transparented with a transparent solution, sealed with neutral gum, and observed and photographed under a microscope (no. SQS-600P, Teksqray, China). TUNEL Staining The tissue sections were deparaffinized to water, then subjected to citrate microwave (no. GA2307051, Servicebio, China) repair for 10 min. After incubation with the fluorescent TUNEL solution (no. 1168479590, Roche Group, Switzerland) at 37°C for 1 h, they were washed with PBS, stained with DAPI for 15 min, and then observed by a microscope. Prussian Blue Staining After dewaxing the myocardial tissue sections to water, they were stained with freshly prepared Perls working solution (no. G1424, Solarbio, China) for 30–60 min, washed with distilled water, stained with eosin for 15–30 s, and rinsed with distilled water for 2–3 s. They were then dehydrated through a gradient of alcohol, cleared with a clearing agent, and mounted with neutral gum. The sections were observed and photographed under a microscope. Immunohistochemical Staining The paraffin sections of mouse heart were dewaxed to water, subjected to antigen retrieval by citrate microwave (GA2307051, Servicebio, China), and then treated with 3% hydrogen peroxide (no. G1204, Servicebio, China) to block endogenous peroxidase. The sections were blocked with BSA (no. GC305010, Servicebio, China) for 20 min, reacted with the antibodies EGFR (1:100; no. AF6043, affinity, China), GPX4 (1:200; no. 67763-1-IG, proteintech, China), and Nrf2 (1:100; no ER1706, HUABIO, China) at 4°C overnight, and then incubated with the HRP-labeled goat anti-mouse (1:100; no. GB23301, Servicebio, China) or anti-rabbit (1:100; no. GB22303, Servicebio, China) at 37°C for 30 min. After DAB staining (no. ZL1-9018, ZSbio, China), the nuclei were stained with hematoxylin (no. LM10N13, J&K Scientific, China) for 3 min. Finally, the microscope (no. SQS-600P, Teksqray, China) collected images of the sections and counted the number of positive cells. Transmission Electron Microscope Rat H9C2 cells and mouse myocardial tissues from different treatment groups were pre-fixed with 2.5% glutaraldehyde and then further fixed with 1% osmium tetroxide. After sequential dehydration with acetone, the dehydration agent and Epon-812 embedding agent penetrated, and Epon-812 pure embedding agent was used for embedding. The ultra-thin sections were made using an ultrathin sectioning machine (no. UC7rt, LEICA, Germany) and transferred onto copper slides. The sections were stained with acetic uranyl for 10–15 min and then stained with citrate lead for 1–2 min. The images were collected using a transmission electron microscope (no. JEM-1400FLASH, JEOL, Japan) to observe the presence of ferroptosis characteristics and changes in mitochondrial morphology and structure. Elisa Rat H9C2 cell samples were used for the detection of Fe2+, glutathione (GSH), and oxidized glutathione (GSSG), mouse serum samples were used for CK and CK-MB detection, and mouse myocardial samples were used for the determination of GSH and GSSG. Accurately weigh the myocardial tissue, and use a PBS solution with a mass-volume ratio of 1:9 and a tissue homogenizer (no. KZ-III-F, Servicebio, China) to homogenize the tissue. The homogenate is centrifuged at 5000 g for 10 min, and the supernatant is taken for subsequent detection. All operations were carried out in accordance with the instructions of the reagent kit, including the Fe2+ kit (no. BC5415, Solarbio, China), Rat GSH ELISA kit (no. ZC-36690, ZCIBIO, China), Rat GSSG ELISA kit (no. ZC-37498, ZCIBIO, China), Mouse CK ELISA kit (no. ZC-38268, ZCIBIO, China), Mouse CK-MB ELISA kit (no. ZC-38269, ZCIBIO, China), Mouse GSH ELISA kit (no. ZC-38193, ZCIBIO, China), and Mouse GSSG ELISA kit (no. ZC-38909, ZCIBIO, China). Western Blot Analysis Protein expressions of EGFR, GPX4, p-EGFR (Y1045), p-EGFR (Y1068), p-Nrf2 (S40), solute carrier family 7 member 11 (SLC7A11), and Nrf2 in mouse myocardial tissue were detected by WB. The total protein expressions of CHOP, cleaved-caspase3, EGFR, p-EGFR (Y1045), p-EGFR (Y1068), p-Nrf2 (S40), Nrf2, HO-1 (heme oxygenase-1), NQO1 (NAD (P)H quinone dehydrogenase 1), GPX4, and SLC7A11, as well as the nuclear protein expressions of p-Nrf2 (S40) and Nrf2 in H9C2 cells were also measured. Total proteins and nuclear proteins were extracted from myocardial tissue and cell samples, and the proteins were quantified. After denaturation at high temperature, the proteins were separated on SDS-PAGE (no. G2180-2L, Servicebio, China). The separated proteins were transferred onto PVDF membranes (no. ISEQ00010, Sigma-Aldrich, USA), reacted with antibodies, and visualized with ECL reagent (no. BL520B, Biosharp, China) and chemiluminescence instrument (no. 5200 Multi, Tanon, China). Lamin B and β-actin were used as internal references for nuclear protein and total protein, respectively, to calculate the relative levels of each protein. The antibodies used included CHOP (1:1000; no. 15204-1-AP, Proteintech, China), cleaved-caspase3 (1:1000; no. 9661, Cell Signaling Technology, China), EGFR (1:10000; no. ET1604-44, huabio, China), p-EGFR (Y1045) (1:1000; no. 2237, Cell Signaling Technology, China), p-EGFR (Y1068) (1:2000; no. AF3045, Affinity, China), p-Nrf2 (S40) (1:2000; no. DF7519, Affinity, China), Nrf2 (1:2000; no. HA723302, huabio, China), HO-1 (1:2000; no. ab68477, abcam, UK), NQO1 (1:2000; no. ET1702-50, huabio, China), GPX4 (1:15000; no. A1933, Abclonal, China), SLC7A11 (1:1000; no. HA721868, huabio, China), β-actin (1:50000; no. AC026, Abclonal, China), LaminB (1:10000; no. 12987-1-AP, Proteintech, China), Goat Anti-Rabbit IgG (H+L) HRP (1:8000; no. S0001, Affinity, China), and Goat Anti-mouse IgG (H+L) HRP (1:8000; no. AS003, Abclonal, China). Statistical Analysis All the experimental data were analyzed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA), and were expressed as the mean ± standard deviation (SD). The assumptions of normality (Shapiro–Wilk test) and homogeneity of variances (Levene’s test) were examined for each dataset. In all cases, both assumptions were met. Therefore, comparisons among multiple groups were performed using one‑way ANOVA followed by Tukey’s post hoc test for multiple comparisons. Two‑group comparisons were analyzed using independent samples t‑test. The results were considered to have significant differences between groups when P < 0.05. Results Salvianic Acid A Inhibited Ferroptosis Induced by H/R in H9C2 Cardiomyocytes The optimal dose of Salvianic acid A for H/R-induced H9C2 cells was screened by CCK8 assay, as shown in Figure 1A, the cell activity in the H/R group was meaningfully reduced (P < 0.001). Salvianic acid A significantly promoted cell viability starting from 150 µM (P < 0.05), with a highly significant difference at 200 µM (P < 0.001), and this promoting effect increased with the increase in the dosage, reaching a peak at 300 µM and then decreased (P < 0.001). Therefore, 200 µM was selected as the low-dose group and 300 µM as the high-dose group for the subsequent experiments. The ferroptosis inhibitor Fer-1 was used to compare the effects of Salvianic acid A on cell ferroptosis. It showed that the levels of ROS (Figure 1B) and Fe2+ (Figure 1C) in the H/R group pointedly upregulated (P < 0.001), while Salvianic acid A-low, Salvianic acid A-high, and the Fer-1 groups significantly inhibited their levels in H/R cells (P < 0.05). Additionally, the content of GSH (Figure 1D) and GSH/GSSG (Figure 1F) in the H/R group significantly decreased (P < 0.001), while GSSG (Figure 1E) significantly increased (P < 0.001). The Salvianic acid A-low, Salvianic acid A-high, and the Fer-1 groups significantly promoted GSH and GSH/GSSG in H/R cells, and inhibited GSSG (P < 0.05, Figure 1D–F). TEM results showed that mitochondria in H/R cells were significantly contracted in the cytoplasm, the rough endoplasmic reticulum expanded in a cystic shape, and ferroptosis characteristic changes were observed (Figure 1G). The mitochondria in the samples of the Salvianic acid A-low group were contracted, while those in the Salvianic acid A-high and the Fer-1 groups were slightly contracted, and the ferroptosis characteristics were reduced compared to the H/R group (Figure 1G). WB results displayed that the expressions of ferroptosis-related marker proteins GPX4 and SLC7A11 were significantly decreased in the H/R group (P < 0.001, Figure 1H and I). The Salvianic acid A-low, Salvianic acid A-high, and the Fer-1 groups significantly promoted their expressions in the H/R cells (P < 0.001, Figure 1H and I).Figure 1Salvianic acid A inhibited ferroptosis induced by H/R in H9C2 cells. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). (A) CCK8 assay to detect the viability of H/R cells treated with different concentrations of Salvianic acid A, and to screen the optimal dosage. (B) Flow cytometry to detect the intensity of lipid-ROS in cells. (C) Concentration of Fe2+ in cells of each treatment group. (D) GSH content in each group. (E) GSSG content in each group. (F) Ratio of GSH/GSSG in each group. (G) Transmission electron microscopy to observe the ferroptosis status of cells in each treatment group. Magnification: 25000×. The red arrow points to the mitochondria, and the yellow arrow points to the endoplasmic reticulum. (H) WB to detect the expressions of ferroptosis marker proteins GPX4 and SLC7A11. (I) Statistical bar chart of relative protein expression levels. N =3, ***P < 0.001, compared with the control group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the H/R group.An infographic of Salvianic acid A effects on H/R H9C2 cells across assays and protein markers.The infographic consists of three rows (A-I) with various charts and images. A line graph (A) shows cell viability against Salvianic acid A concentration, with viability decreasing in H/R compared to Control, then increasing with Salvianic acid A, peaking at 300 micro M. Bar charts (B, C) display lipid-ROS intensity and Fe2+ levels, with H/R being highest and treatment groups lower. D, E, F bar charts show GSH, GSSG and GSH/GSSG levels; H/R is lower in GSH and GSH/GSSG, higher in GSSG compared to Control, with treatment groups showing opposite trends. G features electron microscopy images highlighting mitochondria and endoplasmic reticulum across different conditions. H presents Western blot bands for GPX4, SLC7A11 and beta-actin, showing weaker bands in H/R and stronger in treatment groups. I includes bar charts of relative protein expression for GPX4 and SLC7A11, with H/R lowest and treatment groups higher.Abbreviations: H/R, hypoxia/reoxygenation; lipid-ROS, lipid reactive oxygen species; GSH, glutathione; GSSG, oxidized glutathione; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11. Salvianic acid A inhibited ferroptosis induced by H/R in H9C2 cells. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). (A) CCK8 assay to detect the viability of H/R cells treated with different concentrations of Salvianic acid A, and to screen the optimal dosage. (B) Flow cytometry to detect the intensity of lipid-ROS in cells. (C) Concentration of Fe2+ in cells of each treatment group. (D) GSH content in each group. (E) GSSG content in each group. (F) Ratio of GSH/GSSG in each group. (G) Transmission electron microscopy to observe the ferroptosis status of cells in each treatment group. Magnification: 25000×. The red arrow points to the mitochondria, and the yellow arrow points to the endoplasmic reticulum. (H) WB to detect the expressions of ferroptosis marker proteins GPX4 and SLC7A11. (I) Statistical bar chart of relative protein expression levels. N =3, ***P < 0.001, compared with the control group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the H/R group. To further characterize the protective effect of Salvianic acid A, the cardiomyocyte‑specific injury marker cardiac troponin I (cTnI) was measured in the cell culture supernatant. As shown in Supplementary Figure 2A, H/R injury significantly increased cTnI levels, and Salvianic acid A treatment (both low and high doses) markedly reduced cTnI release, comparable to the ferroptosis inhibitor Fer‑1 (P < 0.01). Additionally, to determine whether the protective effect of Salvianic acid A is specific to ferroptosis, the expressions of cleaved-caspase‑3 (apoptosis) and CHOP (ER stress‑induced apoptosis) were examined by Western blot. As shown in Supplementary Figure 2B, H/R injury significantly increased both cleaved-caspase‑3 and CHOP expression (P < 0.001). However, Salvianic acid A treatment did not reduce their expression (P > 0.05), indicating that the protective effect of Salvianic acid A is not mediated by inhibition of apoptosis or ER stress, but rather specifically through inhibition of ferroptosis. In summary, ferroptosis was activated in H/R, while Salvianic acid A significantly inhibited this process. Salvianic Acid A Promoted Nrf2 Expression and Nuclear Translocation in H9C2 Induced by H/R Nrf2 is regarded as an important transcriptional regulator that plays a role in anti-ferroptosis. The immunofluorescence results showed that the expression of Nrf2 was pointedly decreased in the H/R group (P < 0.001, Figure 2A and B), and it was mainly expressed in the cytoplasm (Figure 2A). The Salvianic acid A-low and Salvianic acid A-high groups significantly promoted the expression of Nrf2 and induced their nuclear translocation in the H/R group (P < 0.001, Figure 2A and B). The protein detection results showed that the expression of Nrf2 in the nuclear protein and total protein of the H/R group was significantly decreased, and the Salvianic acid A-low and Salvianic acid A-high groups significantly promoted its expression in the nuclear and total protein of the H/R group (P < 0.001, Figure 2C and D). In addition, the protein expressions of HO-1 and NQO1 in the H/R group were significantly reduced, and the Salvianic acid A-low and Salvianic acid A-high groups significantly promoted their protein expressions in the H/R group (P < 0.001, Figure 2E and F). The gene detection results also showed that the Salvianic acid A-low and Salvianic acid A-high groups significantly promoted the gene expressions of HO-1 and NQO1 in the H/R group (P < 0.01, Figure 2G), but not affect the gene level of Nrf2 (P > 0.05, Figure 2G).Figure 2Salvianic acid A promoted the expression and nuclear translocation of Nrf2 in H9C2 cardiomyocytes induced by H/R. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). (A) Immunofluorescence staining to observe the co-localization of Nrf2 expression and the nucleus. Magnification: 200×. (B) Statistical bar chart of the mean fluorescence intensity of Nrf2. (C) WB was used to detect the expressions of Nrf2 and p-Nrf2 (S40) in the total cellular protein, as well as in the nuclear protein. (D) Statistical bar chart of the relative protein expression levels. (E) WB was used to detect the expressions of Nrf2 downstream targets HO-1 and NQO1. (F) Statistical bar chart of the relative protein expression levels. (G) RT-PCR detected the expression of Nrf2 and its downstream transcriptional regulatory genes Hmox1 and Nqo1. N =3, *P < 0.05, ***P < 0.001, compared with the control group; ##P < 0.01, ###P < 0.001, compared with the H/R group.A multi-panel scientific infographic on Nrf2, HO-1 and NQO1 changes with Salvianic acid A in H/R.The image A showing immunofluorescence micrographs arranged in 3 rows (Nrf2, DAPI, Merge) and 4 columns (control, H/R, Salvianic acid A-low, Salvianic acid A-high). Nrf2 signal appears reduced in H/R and higher in Salvianic acid A-low and Salvianic acid A-high; merged views show more Nrf2 signal overlapping nuclei in the Salvianic acid A groups. The image B showing a bar chart with x-axis labels: Control, H/R, Salvianic acid A-low, Salvianic acid A-high; y-axis label: Mean fluorescence intensity of Nrf2. Bars are lowest for H/R and higher for Salvianic acid A-low and Salvianic acid A-high, with Salvianic acid A-high highest. The image C showing Western blots for Nrf2 and p-Nrf2(S40) with LaminB (66 kDa) and beta-actin (42 kDa) controls and molecular weights labeled 100 kDa for Nrf2 and p-Nrf2(S40). The image D showing four bar charts with x-axis labels: Control, H/R, Salvianic acid A-low, Salvianic acid A-high; y-axis label: Relative protein expression (normal to LaminB) for two charts and Relative protein expression (normal to beta-actin) for two charts. In each chart, H/R is lowest and Salvianic acid A-low and Salvianic acid A-high are higher, with Salvianic acid A-high highest. The image E showing Western blots for HO-1 (35–45 kDa), NQO1 (35–45 kDa) and beta-actin (42 kDa). The image F showing two bar charts with x-axis labels: Control, H/R, Salvianic acid A-low, Salvianic acid A-high; y-axis label: Relative protein expression (normal to beta-actin). H/R is lowest and Salvianic acid A-low and Salvianic acid A-high are higher. The image G showing three bar charts with x-axis labels: Control, H/R, Salvianic acid A-low, Salvianic acid A-high; y-axis label: Relative mRNA expression (normal to beta-actin). Nrf2 mRNA bars are similar across groups, while HO-1 and NQO1 mRNA are lower in H/R and higher in Salvianic acid A-low and Salvianic acid A-high. Overall message: Salvianic acid A groups show higher Nrf2-related signals than H/R across fluorescence and protein and downstream targets.Abbreviations: H/R, hypoxia/reoxygenation; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase-1; NQO1, NAD (P)H quinone dehydrogenase 1. Salvianic acid A promoted the expression and nuclear translocation of Nrf2 in H9C2 cardiomyocytes induced by H/R. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). (A) Immunofluorescence staining to observe the co-localization of Nrf2 expression and the nucleus. Magnification: 200×. (B) Statistical bar chart of the mean fluorescence intensity of Nrf2. (C) WB was used to detect the expressions of Nrf2 and p-Nrf2 (S40) in the total cellular protein, as well as in the nuclear protein. (D) Statistical bar chart of the relative protein expression levels. (E) WB was used to detect the expressions of Nrf2 downstream targets HO-1 and NQO1. (F) Statistical bar chart of the relative protein expression levels. (G) RT-PCR detected the expression of Nrf2 and its downstream transcriptional regulatory genes Hmox1 and Nqo1. N =3, *P < 0.05, ***P < 0.001, compared with the control group; ##P < 0.01, ###P < 0.001, compared with the H/R group. Salvianic Acid A Protected H/R-Induced Ferroptosis by Activating Nrf2 To further confirm the role of Nrf2 in the protection of cardiomyocytes from H/R-induced ferroptosis by Salvianic acid A, the Nrf2 inhibitor ML385 was used for treatment. The CCK8 results showed that the cell viability in the H/R group was significantly decreased, while Salvianic acid A significantly promoted the cell viability in the H/R group (P < 0.001, Figure 3A). But ML385 did not affect the promoting effect of Salvianic acid A on cell viability (P > 0.05, Figure 3A). As shown previously, the ROS content in the H/R group was significantly increased, while Salvianic acid A significantly inhibited the ROS content in the H/R group (P < 0.001, Figure 3B). And ML385 reversed the inhibitory effects of Salvianic acid A on the ROS content in the H/R cells (P < 0.001, Figure 3B). Similarly, ML385 reversed the regulatory effect of Salvianic acid A on the contents of GSH, GSSG, and GSH/GSSG in the H/R cells (P < 0.05, Figure 3C). Moreover, ML385 meaningfully repressed the enhancement of Nrf2 expression both in the nuclear and total proteins induced by Salvianic acid A in H/R cells (P < 0.001, Figure 3D and E), as well as the promoting effects on GPX4 and SLC7A11 (P < 0.001, Figure 3D and F). This confirmed that Salvianic acid A inhibited H/R-induced ferroptosis by activating Nrf2.Figure 3Salvianic acid A protected cardiomyocytes from ferroptosis induced by H/R through activating Nrf2. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). Salvianic acid A was used at 300 μM where indicated. (A) CCK8 assay for cell proliferation activity. (B) Flow cytometry for lipid-ROS levels in cells. (C) ELISA for cellular GSH, GSSG, and GSH/GSSG. (D) The expression of Nrf2 in nuclear proteins and the expression of Nrf2, GPX4 and SLC7A11 in total cell proteins were detected by WB. (E) Statistical bar chart of the relative expression levels of Nrf2 protein. (F) Statistical bar chart of the relative expression levels of GPX4 and SLC7A11 proteins. N =3, **P < 0.01, ***P < 0.001, compared with the control group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the H/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A group.A set of 6 bar graphs and 1 blot image showing cardiomyocyte viability, oxidative stress and protein expression.The image A showing a bar graph with y-axis label Cell viability percent and range 70 to 110. The x-axis categories are Control, H slash R, Salvianic acid A, Salvianic acid A plus ML385. Approximate bar heights: Control about 100, H slash R about 75, Salvianic acid A about 85, Salvianic acid A plus ML385 about 82. The image B showing a bar graph with y-axis label Mean fluorescence intensity of ROS and range 0 to 80000. The x-axis categories are Control, H slash R, Salvianic acid A, Salvianic acid A plus ML385. Approximate bar heights: Control about 25000, H slash R about 58000, Salvianic acid A about 38000, Salvianic acid A plus ML385 about 50000. The image C showing three bar graphs. Left graph y-axis label GSH (millimole per liter) range 0 to 30; x-axis categories Control, H slash R, Salvianic acid A, Salvianic acid A plus ML385; approximate bars: 25, 18, 22, 16. Middle graph y-axis label GSSG (millimole per liter) range 600 to 1000; approximate bars: 670, 900, 740, 850. Right graph y-axis label GSH slash GSSG range 0.00 to 0.05; approximate bars: 0.038, 0.018, 0.030, 0.020. The image D showing a western blot style panel with rows labeled Nrf2, LaminB, Nrf2, GPX4, SLC7A11, beta-actin and molecular weights at right: 100 kilodalton, 66 kilodalton, 100 kilodalton, 20 kilodalton, 55 kilodalton, 42 kilodalton. Lanes are labeled Control, H slash R, Salvianic acid A, Salvianic acid A plus ML385. The image E showing two bar graphs. Left graph y-axis label Relative protein expression of Nrf2 (nor of LaminB) range 0 to 2.0; x-axis categories Control, H slash R, Salvianic acid A, Salvianic acid A plus ML385; approximate bars: 1.0, 0.1, 1.8, 0.1. Right graph y-axis label Relative protein expression of Nrf2 (nor of beta-actin) range 0 to 2.5; approximate bars: 1.0, 0.4, 1.9, 0.8. The image F showing two bar graphs. Left graph y-axis label Relative protein expression of GPX4 (nor of beta-actin) range 0 to 2.0; x-axis categories Control, H slash R, Salvianic acid A, Salvianic acid A plus ML385; approximate bars: 1.0, 0.5, 1.5, 0.2. Right graph y-axis label Relative protein expression of SLC7A11 (nor of beta-actin) range 0 to 2.0; approximate bars: 1.0, 0.3, 1.3, 0.5.Abbreviations: H/R, hypoxia/reoxygenation; lipid-ROS, lipid reactive oxygen species; GSH, glutathione; GSSG, oxidized glutathione; Nrf2, nuclear factor erythroid 2-related factor 2; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11. Salvianic acid A protected cardiomyocytes from ferroptosis induced by H/R through activating Nrf2. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). Salvianic acid A was used at 300 μM where indicated. (A) CCK8 assay for cell proliferation activity. (B) Flow cytometry for lipid-ROS levels in cells. (C) ELISA for cellular GSH, GSSG, and GSH/GSSG. (D) The expression of Nrf2 in nuclear proteins and the expression of Nrf2, GPX4 and SLC7A11 in total cell proteins were detected by WB. (E) Statistical bar chart of the relative expression levels of Nrf2 protein. (F) Statistical bar chart of the relative expression levels of GPX4 and SLC7A11 proteins. N =3, **P < 0.01, ***P < 0.001, compared with the control group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the H/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A group. Salvianic Acid A Promoted EGFR Activation Induced by H/R in H9C2 Cardiomyocytes Activation of EGFR has been proven to have a protective effect on myocardial I/R injury. Molecular docking revealed that the binding affinity of Salvianic acid A to EGFR was −5.03 kcal/mol, indicating that Salvianic acid A has a good binding potential with EGFR. Specifically, Salvianic acid A forms electrostatic forces with EGFR residues ARG752 and ARG681, and hydrogen bonds with ALA743, MET742, LEU680, LEU753, LEU679, LEU754, GLY755, and TRP707, suggesting a good binding activity between them (Supplementary Figure 1). The detection results of EGFR and its phosphorylated protein expression showed that EGFR expression did not differ significantly across any of the cell groups (P > 0.05, Figure 4A and B). However, the expressions of p-EGFR (Y1045) and p-EGFR (Y1068) in the H/R group were significantly decreased, while the Salvianic acid A-low and Salvianic acid A-high groups significantly promoted their expressions in the cells of the H/R group (P < 0.001, Figure 4A and B). The immunofluorescence findings aligned with the WB results. That is, Salvianic acid A significantly promoted the levels of p-EGFR (Y1045) and p-EGFR (Y1068) in the cells of the H/R model group (P < 0.001, Figure 4C–F).Figure 4Salvianic acid A promoted the activation of EGFR in H9C2 induced by H/R. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). (A) WB was used to detect the expressions of EGFR, p-EGFR (Y1045), and p-EGFR (Y1068). (B) Statistical bar chart of relative protein expression levels. (C) Immunofluorescence staining was used to detect the expression of p-EGFR (Y1045). Magnification: 200×. (D) Statistical bar chart of the mean fluorescence intensity of p-EGFR (Y1045). (E) Immunofluorescence staining was used to detect the expression of p-EGFR (Y1068). Magnification: 200×. (F) Statistical bar chart of the mean fluorescence intensity of p-EGFR (Y1068). N =3, ***P < 0.001, compared with the control group; ###P < 0.001, compared with the H/R group.EGFR phosphorylation under H/R and Salvianic acid A: western blot, bar charts, immunofluorescence.Image A displays a western blot for EGFR, p-EGFR (Y1045), p-EGFR (Y1068) and beta-actin across Control, H/R, Salvianic acid A-low and Salvianic acid A-high groups. EGFR and p-EGFR have molecular weights of 140-180 kDa, while beta-actin is 42 kDa. Image B presents bar charts showing relative protein expression: EGFR (1.0, 1.0, 1.2, 1.1), p-EGFR (Y1045) (1.0, 0.1, 2.2, 3.8) and p-EGFR (Y1068) (1.0, 0.1, 2.0, 4.2) with statistical significance indicated. Image C features immunofluorescence micrographs for p-EGFR (Y1045), DAPI and Merge, showing weakest staining in H/R and stronger in Salvianic acid A groups. Image D shows a bar chart of mean fluorescence intensity for p-EGFR (Y1045): 10, 4, 15, 26, with significance markers. Image E displays micrographs for p-EGFR (Y1068), DAPI and Merge, with weakest staining in H/R and stronger in Salvianic acid A groups. Image F presents a bar chart of mean fluorescence intensity for p-EGFR (Y1068): 10, 3, 14, 27, with significance markers.Abbreviations: H/R, hypoxia/reoxygenation; EGFR, epidermal growth factor receptor. Salvianic acid A promoted the activation of EGFR in H9C2 induced by H/R. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). (A) WB was used to detect the expressions of EGFR, p-EGFR (Y1045), and p-EGFR (Y1068). (B) Statistical bar chart of relative protein expression levels. (C) Immunofluorescence staining was used to detect the expression of p-EGFR (Y1045). Magnification: 200×. (D) Statistical bar chart of the mean fluorescence intensity of p-EGFR (Y1045). (E) Immunofluorescence staining was used to detect the expression of p-EGFR (Y1068). Magnification: 200×. (F) Statistical bar chart of the mean fluorescence intensity of p-EGFR (Y1068). N =3, ***P < 0.001, compared with the control group; ###P < 0.001, compared with the H/R group. Salvianic Acid A Improved H/R-Induced Cardiomyocyte Ferroptosis by Activating EGFR SiRNA-EGFR was used to silence EGFR expression in cells, to verify the role of EGFR activation in the improvement of cardiomyocyte ferroptosis induced by H/R by Salvianic acid A. Results showed that siRNA-EGFR markedly blocked the enhancement of H/R cell activity by Salvianic acid A and also negated its suppressive impact on ROS and Fe2⁺ levels (P < 0.05, Figure 5A–C). Similarly, siRNA-EGFR significantly inhibited the regulatory effects of Salvianic acid A on GSH, GSSG, and the ratio of GSH/GSSG in H/R cells (P < 0.05, Figure 5D). TEM analysis revealed that siRNA-EGFR markedly attenuated the suppressive effect of Salvianic acid A on ferroptosis in H/R cells (Figure 5E). It was confirmed that Salvianic acid A inhibited H/R-induced cardiomyocyte ferroptosis by activating EGFR.Figure 5Salvianic acid A improved H/R-induced cardiomyocyte ferroptosis by activating EGFR. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). Salvianic acid A was used at 300 μM where indicated. (A) CCK8 assay for cell proliferation activity. (B) Flow cytometry for lipid reactive oxygen species (lipid-ROS) levels in cells. (C) Statistical graph of Fe2+ content in cells. (D) ELISA for cell GSH and GSSG contents, and calculation of the GSH/GSSG ratio. (E) Transmission electron microscopy observation of changes in mitochondrial ferroptosis characteristics of cells. Magnification: 25000×. The red arrow points to the mitochondria, and the yellow arrow points to the endoplasmic reticulum. N =3, ***P < 0.001, compared with the control group; ##P < 0.01, ###P < 0.001, compared with the H/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A+siRNA-NC group.A composite figure with 6 bar charts and 5 microscopy images of cardiomyocyte ferroptosis measures.The image A showing a bar chart of Cell viability (percent) on the vertical axis from 70 to 110 and groups on the horizontal axis: Control, H slash R, Salvianic acid A, Salvianic acid A plus siRNA-NC, Salvianic acid A plus siRNA-EGFR. Bar heights: Control about 100, H slash R about 70, Salvianic acid A about 82, Salvianic acid A plus siRNA-NC about 81, Salvianic acid A plus siRNA-EGFR about 77. The image B showing a bar chart of Mean fluorescence intensity of ROS on the vertical axis from 30000 to 55000 and the same five groups on the horizontal axis. Bar heights: Control about 35000, H slash R about 51000, Salvianic acid A about 40000, Salvianic acid A plus siRNA-NC about 39500, Salvianic acid A plus siRNA-EGFR about 47500. The image C showing a bar chart of Fe2 plus (micro-mol per gram protein) on the vertical axis from 0 to 8 and the same five groups on the horizontal axis. Bar heights: Control about 3.0, H slash R about 6.6, Salvianic acid A about 5.0, Salvianic acid A plus siRNA-NC about 4.8, Salvianic acid A plus siRNA-EGFR about 6.3. The image D showing three bar charts with the same five groups on each horizontal axis. Left chart: GSH (millimol per liter) on the vertical axis from 0 to 30; bars are Control about 24, H slash R about 14, Salvianic acid A about 20, Salvianic acid A plus siRNA-NC about 21, Salvianic acid A plus siRNA-EGFR about 16. Middle chart: GSSG (millimol per liter) on the vertical axis from 600 to 1000; bars are Control about 690, H slash R about 900, Salvianic acid A about 760, Salvianic acid A plus siRNA-NC about 750, Salvianic acid A plus siRNA-EGFR about 840. Right chart: GSH over GSSG on the vertical axis from 0.00 to 0.05; bars are Control about 0.034, H slash R about 0.015, Salvianic acid A about 0.028, Salvianic acid A plus siRNA-NC about 0.028, Salvianic acid A plus siRNA-EGFR about 0.020. The image E showing five transmission electron microscopy images labeled control, H slash R, Salvianic acid A, Salvianic acid A plus si-NC and Salvianic acid A plus si-EGFR. Each micrograph contains arrows pointing to mitochondria and endoplasmic reticulum, with text labels including RER and M. Scale bars are shown at the bottom right of each micrograph.Abbreviations: H/R, hypoxia/reoxygenation; lipid-ROS, lipid reactive oxygen species; GSH, glutathione; GSSG, oxidized glutathione. Salvianic acid A improved H/R-induced cardiomyocyte ferroptosis by activating EGFR. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). Salvianic acid A was used at 300 μM where indicated. (A) CCK8 assay for cell proliferation activity. (B) Flow cytometry for lipid reactive oxygen species (lipid-ROS) levels in cells. (C) Statistical graph of Fe2+ content in cells. (D) ELISA for cell GSH and GSSG contents, and calculation of the GSH/GSSG ratio. (E) Transmission electron microscopy observation of changes in mitochondrial ferroptosis characteristics of cells. Magnification: 25000×. The red arrow points to the mitochondria, and the yellow arrow points to the endoplasmic reticulum. N =3, ***P < 0.001, compared with the control group; ##P < 0.01, ###P < 0.001, compared with the H/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A+siRNA-NC group. To directly test whether the protective effect of EGFR is specifically mediated through ferroptosis, a rescue experiment was performed using the ferroptosis inhibitor Fer‑1 in combination with EGFR knockdown (Supplementary Figure 2C–E). It found that EGFR knockdown (siRNA‑EGFR) abolished the protective effect of Salvianic acid A on cell viability, and addition of Fer‑1 fully rescued cell viability to levels comparable to the Salvianic acid A group (P < 0.001, Supplementary Figure 2C). Similarly, Supplementary Figure 2D showed that siRNA‑EGFR increased lipid‑ROS levels, and Fer‑1 completely reversed this effect (P < 0.001). Supplementary Figure 2E demonstrated that siRNA‑EGFR increased Fe2⁺ accumulation, which was fully reversed by Fer‑1 (P < 0.01). These results provide direct evidence that the protective effect of EGFR activation is specifically mediated through inhibition of ferroptosis. In summary, Salvianic acid A improved H/R-induced cardiomyocyte ferroptosis by activating EGFR, and this protective effect was specifically mediated through inhibition of ferroptosis. Salvianic Acid A Promoted the Nuclear Translocation and Expression of Nrf2 by Activating EGFR Nrf2 is believed to be located downstream of the EGFR signaling pathway. The analysis of Nrf2 localization showed that siRNA-EGFR significantly inhibited the promoting effects of Salvianic acid A on the nuclear translocation of Nrf2 in H/R cells (Figure 6A), but had no significant effect on its fluorescence intensity (P > 0.05, Figure 6B). The WB detection results showed that siRNA-EGFR meaningfully repressed the promoting effects of Salvianic acid A on the expression of Nrf2 in nuclear and total proteins of H/R cells (P < 0.001, Figure 6C–E), and also repressed the expression of EGFR in H/R cells treated with Salvianic acid A (P < 0.001, Figure 6C and F). In addition, siRNA-EGFR significantly inhibited the promoting effects of Salvianic acid A on p-EGFR (Y1045), p-EGFR (Y1068), ferroptosis protein GPX4, and SLC7A11 in H/R cells (P < 0.001, Figure 6C, G and H). In addition, the gene detection results also showed that siRNA-EGFR meaningfully repressed the encouraging effect of Salvianic acid A on the gene levels of Hmox1 and Nqo1 in H/R cells (P < 0.01, Figure 6I). This confirmed that Salvianic acid A promoted the nuclear translocation and expression of Nrf2 in H/R cells by activating EGFR, ultimately inhibiting ferroptosis.Figure 6Salvianic acid A promoted the nuclear translocation and expression of Nrf2 by activating EGFR. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). Salvianic acid A was used at 300 μM where indicated. (A) Immunofluorescence staining to observe the expression and localization of Nrf2. Magnification: 200×. (B) Statistical bar chart of the mean fluorescence intensity of Nrf2. (C) WB was used to detect the protein expression levels of Nrf2 and p-Nrf2 (S40) in intracellular nuclear proteins, as well as the protein expression levels of Nrf2, p-Nrf2 (S40), EGFR, p-EGFR (Y1045), p-EGFR (Y1068), GPX4, and SLC7A11 in total intracellular proteins. (D) Statistical bar chart of the protein expressions of Nrf2 and p-Nrf2 (S40) in intracellular nuclear proteins. (E) Statistical bar chart of the protein expressions of Nrf2 and p-Nrf2 (S40) in total intracellular proteins. (F) Statistical bar chart of the protein expression of EGFR in total intracellular proteins. (G) Statistical bar chart of the protein expressions of p-EGFR (Y1045) and p-EGFR (Y1068) in total intracellular proteins. (H) Statistical bar chart of the protein expressions of GPX4 and SLC7A11 in total intracellular proteins. (I) RT-PCR was used to detect the expression of Nrf2 and its downstream transcriptionally regulated Hmox1 and Nqo1 genes. N =3, *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control group; ##P < 0.01, ###P < 0.001, compared with the H/R group; &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A+siRNA-NC group.A multi-part scientific infographic on Salvianic acid A, si-EGFR and Nrf2 under H/R.The image A showing immunofluorescence results arranged in 3 rows (Nrf2, DAPI, Merge) and 5 columns labeled: control, H/R, Salvianic acid A, Salvianic acid A plus si-NC, Salvianic acid A plus si-EGFR. The image B showing a bar graph of Nrf2 signal. X-axis: Control, H/R, Salvianic acid A, Salvianic acid A plus si-NC, Salvianic acid A plus si-EGFR. Y-axis: Mean fluorescence intensity (a.u.), with tick values 0, 10, 20, 30, 40. Bars show H/R lower than Control and Salvianic acid A higher than H/R; Salvianic acid A plus si-NC is similar to Salvianic acid A; Salvianic acid A plus si-EGFR is lower than Salvianic acid A. The image C showing Western blot bands with labels and molecular weights: Nrf2 100 kDa; p-Nrf2 (S40) 100 kDa; LaminB 66 kDa; Nrf2 100 kDa; p-Nrf2 (S40) 100 kDa; EGFR 140 to 180 kDa; p-EGFR (Y1045) 140 to 180 kDa; p-EGFR (Y1068) 140 to 180 kDa; GPX4 20 kDa; SLC7A11 55 kDa; beta-actin 42 kDa. Lane labels: Control, H/R, Salvianic acid A, Salvianic acid A plus si-NC, Salvianic acid A plus si-EGFR. The image D showing two bar graphs titled Relative protein expression (normal to LaminB). X-axis: Control, H/R, Salvianic acid A, Salvianic acid A plus si-NC, Salvianic acid A plus si-EGFR. Y-axis: Relative protein expression (normal to LaminB) (a.u.). The left graph corresponds to Nrf2 and the right graph corresponds to p-Nrf2 (S40), with higher bars for Salvianic acid A and Salvianic acid A plus si-NC than H/R and lower bars for Salvianic acid A plus si-EGFR. The image E showing two bar graphs titled Relative protein expression (normal to beta-actin). X-axis: Control, H/R, Salvianic acid A, Salvianic acid A plus si-NC, Salvianic acid A plus si-EGFR. Y-axis: Relative protein expression (normal to beta-actin) (a.u.). The left graph corresponds to GPX4 and the right graph corresponds to SLC7A11, with H/R lower than Control, Salvianic acid A higher than H/R, Salvianic acid A plus si-NC similar to Salvianic acid A and Salvianic acid A plus si-EGFR reduced. The image F showing a bar graph titled Relative protein expression (normal to EGFR). X-axis: Control, H/R, Salvianic acid A, Salvianic acid A plus si-NC, Salvianic acid A plus si-EGFR. Y-axis: Relative protein expression (normal to EGFR) (a.u.), with tick values 0.0, 0.5, 1.0, 1.5. The Salvianic acid A plus si-EGFR bar is near 0, while the other groups are near 1.0. Statistical markers (asterisks, number signs and and signs) appear above bars to denote significant differences.Abbreviations: H/R, hypoxia/reoxygenation; Nrf2, nuclear factor erythroid 2-related factor 2; EGFR, epidermal growth factor receptor; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11; HO-1, heme oxygenase-1; NQO1, NAD (P)H quinone dehydrogenase 1.Figure 6Continued.Seven bar charts display protein and mRNA expression across various treatment groups.Panel G: Two bar charts. First chart shows relative protein expression of Hmox1 normalized to beta-actin. X-axis: Control, IIR, Salvianolic acid A, XAV939-NC, XAV939-EGFR. Y-axis: 0 to 2.5. Control is 1.0, IIR decreases to 0.2, Salvianolic acid A increases to 1.9, XAV939-NC is 2.0, XAV939-EGFR reduces to 0.6. Second chart shows PGF protein expression. X-axis: same groups. Y-axis: 0 to 3.0. Control is 1.0, IIR decreases to 0.1, Salvianolic acid A increases to 2.1, XAV939-NC is 2.2, XAV939-EGFR reduces to 0.2. Panel H: Two bar charts. First chart shows SLC7A11 protein expression. X-axis: same groups. Y-axis: 0 to 2.5. Control is 1.0, IIR decreases to 0.3, Salvianolic acid A increases to 2.2, XAV939-NC is 2.1, XAV939-EGFR reduces to 0.7. Second chart shows SLC7A11 protein expression. X-axis: same groups. Y-axis: 0 to 2.0. Control is 1.0, IIR decreases to 0.5, Salvianolic acid A increases to 1.5, XAV939-NC is 1.6, XAV939-EGFR reduces to 0.9. Panel I: Three bar charts. First chart shows relative messenger ribonucleic acid expression. X-axis: same groups. Y-axis: 0.6 to 1.1. Control is 1.0, IIR is 0.8, Salvianolic acid A is 0.8, XAV939-NC is 0.82, XAV939-EGFR is 0.83. Second chart shows Hmox1 messenger ribonucleic acid expression. X-axis: same groups. Y-axis: 0 to 2.0. Control is 1.0, IIR decreases to 0.5, Salvianolic acid A increases to 1.3, XAV939-NC is 1.3, XAV939-EGFR reduces to 0.5. Third chart shows PGF messenger ribonucleic acid expression. X-axis: same groups. Y-axis: 0 to 2.5. Control is 1.0, IIR decreases to 0.5, Salvianolic acid A increases to 1.5, XAV939-NC is 1.4, XAV939-EGFR reduces to 0.4. Overall, IIR decreases expression, Salvianolic acid A and XAV939-NC increase expression, while XAV939-EGFR reduces expression across protein and messenger ribonucleic acid levels. Salvianic acid A promoted the nuclear translocation and expression of Nrf2 by activating EGFR. Cells were pre-treated with the indicated drugs during the 24 h synchronization period, followed by hypoxia (12 h) and reoxygenation (24 h). Salvianic acid A was used at 300 μM where indicated. (A) Immunofluorescence staining to observe the expression and localization of Nrf2. Magnification: 200×. (B) Statistical bar chart of the mean fluorescence intensity of Nrf2. (C) WB was used to detect the protein expression levels of Nrf2 and p-Nrf2 (S40) in intracellular nuclear proteins, as well as the protein expression levels of Nrf2, p-Nrf2 (S40), EGFR, p-EGFR (Y1045), p-EGFR (Y1068), GPX4, and SLC7A11 in total intracellular proteins. (D) Statistical bar chart of the protein expressions of Nrf2 and p-Nrf2 (S40) in intracellular nuclear proteins. (E) Statistical bar chart of the protein expressions of Nrf2 and p-Nrf2 (S40) in total intracellular proteins. (F) Statistical bar chart of the protein expression of EGFR in total intracellular proteins. (G) Statistical bar chart of the protein expressions of p-EGFR (Y1045) and p-EGFR (Y1068) in total intracellular proteins. (H) Statistical bar chart of the protein expressions of GPX4 and SLC7A11 in total intracellular proteins. (I) RT-PCR was used to detect the expression of Nrf2 and its downstream transcriptionally regulated Hmox1 and Nqo1 genes. N =3, *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control group; ##P < 0.01, ###P < 0.001, compared with the H/R group; &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A+siRNA-NC group. Continued. Salvianic Acid A Improved Myocardial I/R Injury in Mice via EGFR Further, the effects of Salvianic acid A on myocardial I/R were analyzed through in vivo experiments using EGFR inhibitor AG1478 and agonist EGF. The echocardiographic results of the mice were shown in Figure 7A. The statistical results indicated that the left ventricular ejection fraction (LVEF) and left ventricular short-axis shortening rate (LVFS) of I/R mice were significantly decreased (P < 0.001), while Salvianic acid A significantly improved both LVEF and LVFS (P < 0.001), and this improvement effect was reversed by AG1478 and further enhanced by EGF (P < 0.05, Figure 7B). The results of mouse TTC staining were shown in Figure 7C, which found that the myocardial infarct size in I/R mice significantly increased, Salvianic acid A significantly reduced the myocardial infarct size, and this inhibitory effect was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 7C). The pathological staining results show that, the model group had myocardial fiber degeneration and necrosis, with mild inflammatory cell infiltration in the necrotic areas or interstitium, fibrous tissue hyperplasia was observed, and fibroblasts with long oval nuclei and fibrocytes with long spindle-shaped nuclei were visible (Figure 7D). And the degree of lesions in the Salvianic acid A, AG1478, and EGF group was all reduced to varying degrees, the effect of the EGF was superior to that of the Salvianic acid A group, and the Salvianic acid A group was superior to the AG1478 (Figure 7D). Furthermore, the percentage of apoptotic cells in I/R mice significantly increased, Salvianic acid A significantly inhibited cell apoptosis, and this inhibitory effect was reversed by AG1478 (P < 0.01, Figure 7E and F). Similarly, the contents of CK, CK-MB, and cTnI in the serum of I/R mice significantly increased, Salvianic acid A significantly inhibited their contents, and this inhibitory effect was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 7G).Figure 7Salvianic acid A improved myocardial I/R injury in mice through EGFR. (A) Results of echocardiography for each group of mice. (B) Statistical bar charts of left ventricular ejection fraction (LVEF) and left ventricular short-axis shortening rate (LVFS) on echocardiography. N =5. (C) TTC staining was used to observe the percentage of myocardial infarction area. (D) HE staining was used to observe the morphological and structural changes of myocardial tissue. Magnification: 400×. The green arrow indicates the degeneration and necrosis of myocardial cells, the yellow arrow points to fibroblasts, and the black arrow indicates lymphocytes. (E) TUNEL staining was used to observe myocardial cell apoptosis. Magnification: 400×. (F) Statistical bar chart of the percentage of apoptotic cells. (G) The contents of myocardial injury markers CK, CK-MB, and cTnI in serum. N =3, **P < 0.01, ***P < 0.001, compared with the SHAM group; ##P < 0.01, ###P < 0.001, compared with the I/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A group.An infographic showing Salvianic acid A improves mouse cardiac measures after I/R across tests.The infographic compares five groups: SHAM, I/R, Salvianic acid A, Salvianic acid A plus AG1478 and Salvianic acid A plus EGF. It includes: A) Echocardiography images; B) Bar charts for LVEF and LVFS percentages; C) TTC staining images and a bar chart for infarction area percentage; D) HE staining micrographs; E) TUNEL staining micrographs; F) Bar chart for apoptotic cells percentage; G) Bar charts for CK, CK-MB and cTnI levels. I/R group shows lower LVEF and LVFS, higher infarction area, apoptotic cells, CK, CK-MB and cTnI compared to SHAM. Salvianic acid A improves these metrics towards SHAM levels. Salvianic acid A plus AG1478 worsens metrics towards I/R, while Salvianic acid A plus EGF improves them towards Salvianic acid A. Significance is marked with asterisk, hash and ampersand for P < 0.05, P < 0.01 and P < 0.001. Sample sizes are N=5 for echocardiography and N=3 for serum markers.Abbreviations: I/R, ischemia-reperfusion; CK, creatine kinase; CK-MB, creatine kinase MB. Salvianic acid A improved myocardial I/R injury in mice through EGFR. (A) Results of echocardiography for each group of mice. (B) Statistical bar charts of left ventricular ejection fraction (LVEF) and left ventricular short-axis shortening rate (LVFS) on echocardiography. N =5. (C) TTC staining was used to observe the percentage of myocardial infarction area. (D) HE staining was used to observe the morphological and structural changes of myocardial tissue. Magnification: 400×. The green arrow indicates the degeneration and necrosis of myocardial cells, the yellow arrow points to fibroblasts, and the black arrow indicates lymphocytes. (E) TUNEL staining was used to observe myocardial cell apoptosis. Magnification: 400×. (F) Statistical bar chart of the percentage of apoptotic cells. (G) The contents of myocardial injury markers CK, CK-MB, and cTnI in serum. N =3, **P < 0.01, ***P < 0.001, compared with the SHAM group; ##P < 0.01, ###P < 0.001, compared with the I/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A group. Salvianic Acid A Improved Myocardial Ferroptosis in I/R Mice via EGFR TEM was used to observe the ferroptosis of myocardial cells, and found that the cristae of mitochondria were split, the matrix was lost, the integrity of the inner and outer membranes of mitochondria was lost, presenting vacuolation, and the mitochondria were significantly abnormal, showing the characteristics of ferroptosis in I/R mice (Figure 8A). After treatment with Salvianic acid A, the ferroptosis state of the I/R mice was significantly improved (Figure 8A). EGF further promoted the improvement effect of Salvianic acid A on ferroptosis, while AG1478 inhibited its effects (Figure 8A). The Prussian blue staining displayed that the Fe2+ content in myocardial cells of the I/R group significantly increased, and Salvianic acid A significantly inhibited the iron ion content (P < 0.05, Figure 8B and C). This inhibitory effect was reversed by AG1478, but it was not statistically significant (P > 0.01, Figure 8B and C). Similarly, the ROS content in myocardial tissues of I/R mice meaningfully increased, Salvianic acid A significantly inhibited the ROS content, and this inhibitory effect was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 8D). Additionally, the GSSG content in myocardial tissues of the I/R group significantly increased, and GSH and GSH/GSSG significantly decreased (P < 0.001, Figure 8E). Salvianic acid A significantly regulated their expressions in myocardial tissues of the I/R group, and this regulatory effect was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 8E). Immunohistochemistry disclosed that the level of GPX4 in myocardial tissues of the I/R group was significantly decreased, Salvianic acid A significantly increased its expression, and this promoting effect was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 8F). Protein detection results were consistent with immunohistochemistry. Salvianic acid A significantly promoted the levels of GPX4 and SLC7A11 in myocardial tissues of I/R mice, and this promoting effect was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 8G). In summary, Salvianic acid A inhibited ferroptosis of myocardial cells in mice after myocardial I/R by EGFR.Figure 8Salvianic acid A improved myocardial ferroptosis in I/R mice through EGFR. (A) Transmission electron microscopy was used to observe the mitochondrial ferroptosis characteristics in myocardial cells. Magnification: 40000×. The red arrow points to the mitochondria, and the yellow arrow points to the sarcoplasmic reticulum. (B) Prussian blue staining was used to observe iron ion deposition in myocardial cells. Magnification: 400×. (C) The statistical results of the percentage of positive expression area. (D) Flow cytometry was used to detect the content of lipid reactive oxygen species (ROS) in myocardial tissue. (E) ELISA was used to detect GSH, GSSG, and GSH/GSSG in myocardial tissue. (F) Immunohistochemical staining was used to observe GPX4 expression in myocardial tissue. Magnification: 400×. (G) WB was used to detect the expression of ferroptosis proteins GPX4 and SLC7A11 in myocardial tissue. N =3, *P < 0.05, **P < 0.01, ***P < 0.001, compared with the SHAM group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the I/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A group.Multi-panel figure showing Salvianic acid A effects on myocardial ferroptosis in I/R mice.The multi-panel figure illustrates the effects of Salvianic acid A on myocardial ferroptosis in I/R mice. A) Transmission electron microscopy shows mitochondrial changes across groups: SHAM, I/R, Salvianic acid A, Salvianic acid A plus AG1478 and Salvianic acid A plus EGF. B) Prussian blue staining indicates iron deposition. C) Graph shows percentage of positive expression, with I/R increased and reduced by Salvianic acid A. D) ROS intensity is highest in I/R, reduced by Salvianic acid A. E) GSH, GSSG and GSH/GSSG levels are altered, with Salvianic acid A restoring balance. F) GPX4 expression is decreased in I/R, increased by Salvianic acid A. G) Western blot shows GPX4 and SLC7A11 levels, with Salvianic acid A increasing expression. Symbols denote significance compared to SHAM or I/R. Overall, Salvianic acid A reduces ferroptosis, iron and ROS, restoring antioxidant markers, with inhibitors and EGF modifying effects.Abbreviations: I/R, ischemia-reperfusion; GSH, glutathione; GSSG, oxidized glutathione; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11. Salvianic acid A improved myocardial ferroptosis in I/R mice through EGFR. (A) Transmission electron microscopy was used to observe the mitochondrial ferroptosis characteristics in myocardial cells. Magnification: 40000×. The red arrow points to the mitochondria, and the yellow arrow points to the sarcoplasmic reticulum. (B) Prussian blue staining was used to observe iron ion deposition in myocardial cells. Magnification: 400×. (C) The statistical results of the percentage of positive expression area. (D) Flow cytometry was used to detect the content of lipid reactive oxygen species (ROS) in myocardial tissue. (E) ELISA was used to detect GSH, GSSG, and GSH/GSSG in myocardial tissue. (F) Immunohistochemical staining was used to observe GPX4 expression in myocardial tissue. Magnification: 400×. (G) WB was used to detect the expression of ferroptosis proteins GPX4 and SLC7A11 in myocardial tissue. N =3, *P < 0.05, **P < 0.01, ***P < 0.001, compared with the SHAM group; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the I/R group; &P < 0.05, &&P < 0.01, &&&P < 0.001, compared with the Salvianic acid A group. Salvianic Acid A Activated the EGFR/Nrf2 Pathway in I/R Mice The immunohistochemical results showed that in the myocardial tissue of the I/R group, the expressions of EGFR and Nrf2 were meaningfully decreased, Salvianic acid A significantly promoted their expressions, and the promoting effect on EGFR was reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 9A and B). However, AG1478 and EGF had no impact on Nrf2 expression (P > 0.05, Figure 9A and B). WB outcomes showed that the expressions of p-EGFR (Y1045), p-EGFR (Y1068), Nrf2, and p-Nrf2 (S40) were significantly decreased in the I/R mouse myocardium, Salvianic acid A pointedly promoted their expressions, and the promoting effects on p-EGFR (Y1045), p-EGFR (Y1068), and p-Nrf2 (S40) were reversed by AG1478 and further promoted by EGF (P < 0.05, Figure 9C and D). Similarly, AG1478 and EGF had no impact on Nrf2 expression (P > 0.05, Figure 9C and D).Figure 9Salvianic acid A activated the EGFR/Nrf2 in I/R mice. (A) Immunohistochemical staining was used to observe the expressions of EGFR and Nrf2 in myocardial tissue. Magnification: 400×. (B) Statistical bar chart of EGFR and Nrf2 positive-expressing cells. (C) WB was used to detect the expressions of EGFR, p-EGFR (Y1045), p-EGFR (Y1068), Nrf2, and p-Nrf2 (S40) in myocardial tissue. (D) Statistical bar chart of protein relative expression results. N =3, *P < 0.05, **P < 0.01, ***P < 0.001, compared with the SHAM group; ##P < 0.01, ###P < 0.001, compared with the I/R group; &P < 0.05, &&&P < 0.001, compared with the Salvianic acid A group.Immunohistochemical and WB analysis of EGFR and Nrf2 expressions in myocardial tissue.The image A shows immunohistochemical staining of myocardial tissue for EGFR and Nrf2 across different conditions: SHAM, I/R, Salvianic acid A, Salvianic acid A plus AG1478 and Salvianic acid A plus EGF. The image B shows bar charts depicting the number of positive cells for EGFR and Nrf2. The image C shows Western Blot (WB) results for EGFR, p-EGFR (Y1045), p-EGFR (Y1068), Nrf2 and p-Nrf2 (S40) with molecular weights indicated. The image D shows bar charts of relative protein expression for these proteins across the same conditions. Statistical significance is indicated with symbols: asterisk, hash and ampersand, denoting different levels of significance compared to control groups.Abbreviations: I/R, ischemia-reperfusion; Nrf2, nuclear factor erythroid 2-related factor 2; EGFR, epidermal growth factor receptor. Salvianic acid A activated the EGFR/Nrf2 in I/R mice. (A) Immunohistochemical staining was used to observe the expressions of EGFR and Nrf2 in myocardial tissue. Magnification: 400×. (B) Statistical bar chart of EGFR and Nrf2 positive-expressing cells. (C) WB was used to detect the expressions of EGFR, p-EGFR (Y1045), p-EGFR (Y1068), Nrf2, and p-Nrf2 (S40) in myocardial tissue. (D) Statistical bar chart of protein relative expression results. N =3, *P < 0.05, **P < 0.01, ***P < 0.001, compared with the SHAM group; ##P < 0.01, ###P < 0.001, compared with the I/R group; &P < 0.05, &&&P < 0.001, compared with the Salvianic acid A group. Discussion Myocardial I/R injury remains a leading contributor to the rising mortality and morbidity associated with cardiovascular diseases.23 Salvianic acid A, a water-soluble phenolic aromatic acid, exhibits cardioprotective effects.24 This study demonstrated that Salvianic acid A inhibited ferroptosis induced by H/R in H9C2 cardiomyocytes. Concurrently, it promoted the expression and nuclear translocation of Nrf2 and activated EGFR in H/R-induced H9C2 cells. Further investigations revealed that Salvianic acid A activated EGFR signaling, which promoted Nrf2 nuclear translocation and subsequently up‑regulated the Nrf2/GPX4 pathway, thereby inhibiting ferroptosis in H9C2 cardiomyocytes subjected to H/R and conferring cytoprotective effects. In vivo experiments also confirmed that Salvianic acid A activated Nrf2 through EGFR, promoted the activation of the EGFR/Nrf2/GPX4 to prevent ferroptosis in mice, thereby exerting a protecting effect in I/R injury. Salvianic acid A, an active constituent extracted from Salvia miltiorrhiza (Danshen), possesses diverse pharmacological properties including coronary artery dilation, anticoagulation, anti-thrombosis, anti-arrhythmia, and anti-myocardial hypertrophy.12,25 Recent studies have verified that Salvianic acid A promotes the polarization of astrocytes and microglia, attenuates neuroinflammation, and ameliorates cerebral ischemic injury, highlighting its potential as a therapeutic agent for cerebral I/R injury.26 Earlier research further suggested that its cardioprotective effects against I/R injury may be mediated through the inhibition of excessive autophagy and apoptosis via mTOR activation.27 Additionally, Salvianic acid A has been found to protect the heart from I/R injury by suppressing ROS overproduction through the Sirt1/FoxO1/Rab7 pathway.28 In line with earlier findings, this study likewise showed that Salvianic acid A markedly enhanced the viability of H/R-treated cardiomyocytes, improved echocardiographic parameters in I/R mice, reduced myocardial infarct size, diminished cardiomyocyte apoptosis, alleviated myocardial injury, and overall exhibited beneficial therapeutic effects against I/R injury. Beyond the heart, studies have also revealed that Salvianic acid A weakened LPS-induced hepatic stellate cell activation during liver fibrosis by modulating ferroptosis,29 and protected against renal fibrosis by inhibiting ferroptosis.30 Moreover, Salvianic acid A can bind to Nrf2, augmenting its activity and nuclear accumulation, thereby reducing brain injury by inhibiting oxidative damage and ferroptosis.17 In line with these observations, our results indicate that Salvianic acid A significantly inhibited ferroptosis in H/R H9C2 cells and I/R mice, while meaningfully promoting the expression and nuclear translocation of Nrf2. Ferroptosis is a form of cell death driven by iron-dependent oxidative damage, characterized by massive accumulation of Fe2+-dependent lipid peroxides and ROS.31 Accumulating evidence indicates that ferroptosis contributes to myocardial I/R injury, and ferroptosis inhibitors can significantly reduce cell death, enhance cardiomyocyte viability, and improve cardiac function under I/R conditions.32,33 The ferroptotic process involves dysregulation of iron and lipid metabolism, exacerbated lipid peroxidation, and inactivation of GPX4. Inhibition of ferroptosis has emerged as an effective strategy to mitigate the progression of related diseases.33 In both the H/R cell model and the I/R animal model employed in this study, cardiomyocytes exhibited a pronounced increase in ROS levels, elevated Fe2+ accumulation, heightened GSH and GSH/GSSG ratios, reduced GSSG content, and markedly decreased expression of GPX4 and SLC7A11. Salvianic acid A significantly suppressed ferroptosis in cardiomyocytes, and this protective effect was associated with activation of Nrf2. As a key CNC-family nuclear transcription factor, Nrf2 plays an essential role in maintaining intracellular redox homeostasis.34 Studies have identified Nrf2 as a key transcriptional regulator of anti‑ferroptotic defense, enhancing cellular resistance to ferroptosis by up‑regulating genes such as GPX4 and SLC7A11.35 Our results demonstrate that Salvianic acid A significantly promoted Nrf2 nuclear translocation and expression, leading to up‑regulation of downstream targets HO‑1 and NQO1, and reversing the promoting effect of Salvianic acid A on cell activity and the inhibitory effect on ferroptosis induced by H/R. This confirmed that Salvianic acid A exerts H/R protection by activating Nrf2 to regulate GPX4- and SLC7A11-mediated ferroptosis. Moreover, molecular docking analyses indicated that Salvianic acid A binds to EGFR with high affinity, which corresponded with a significant up‑regulation of phosphorylated EGFR at Tyr‑1045 and Tyr‑1068. EGFR, a key transmembrane tyrosine kinase receptor of the ErbB2 family, is activated through phosphorylation at specific residues and participates in various processes.36 Growing evidence suggests that EGFR activation exerts protective effects against myocardial I/R injury.20 Our findings demonstrate that Salvianic acid A activates EGFR, suggesting that its cardioprotective properties may be mediated, at least in part, through this pathway. Additionally, previous reports have shown that Quiescin sulfhydryl oxidase 1 weakened Nrf2 activation by inhibiting EGFR, supporting the notion that Nrf2 acts downstream of EGFR.9 Consistently, in both myocardial I/R injury models and oxidative stress-challenged cardiomyocytes, EGF enhances both the protein expression and transcriptional activity of Nrf2.20 Our data further revealed that EGFR silencing significantly inhibited the promotion effect of Salvianic acid A on Nrf2 nuclear translocation and protein expression in the H/R cell model. Likewise, in I/R mice, pharmacological inhibition of EGFR reversed the Salvianic acid A‑induced up‑regulation of p-Nrf2 (S40), whereas EGFR over‑expression synergized with Salvianic acid A to amplify this effect. In addition, numerous studies indicated that EGFR plays an essential role in regulating cell ferroptosis, and its inhibition promotes ferroptotic cell death in tumor cells, a process linked to altered Nrf2 nucleocytoplasmic distribution and transcriptional activity.37 Upon phosphorylation at sites such as Tyr‑1045, Tyr‑1068, and Thr‑1069, EGFR facilitates Nrf2 phosphorylation at Ser40, a modification crucial for Nrf2 binding to antioxidant response elements and the subsequent induction of downstream antioxidant genes.38 Our study showed that EGFR inhibition meaningfully inhibited the levels of p-EGFR (Y1045), p-EGFR (Y1068), and p-Nrf2 (S40), and consequently attenuated the anti‑ferroptotic effect of Salvianic acid A. In conclusion, Salvianic acid A confers protection against myocardial I/R injury by attenuating ferroptosis through the activation of the EGFR/Nrf2/GPX4 signaling axis.